Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts
Dedee F Murrell, Benjamin S Daniel, Pascal Joly, Luca Borradori, Masayuki Amagai, Takashi Hashimoto, Frédéric Caux, Branka Marinovic, Animesh A Sinha, Michael Hertl, Philippe Bernard, David Sirois, Giuseppe Cianchini, Janet A Fairley, Marcel F Jonkman, Amit G Pandya, David Rubenstein, Detlef Zillikens, Aimee S Payne, David Woodley, Giovanna Zambruno, Valeria Aoki, Carlo Pincelli, Luis Diaz, Russell P Hall, Michael Meurer, Jose M Mascaro Jr, Enno Schmidt, Hiroshi Shimizu, John Zone, Robert Swerlick, Daniel Mimouni, Donna Culton, Jasna Lipozencic, Benjamin Bince, Sergei A Grando, Jean-Claude Bystryn, Victoria P Werth, Dedee F Murrell, Benjamin S Daniel, Pascal Joly, Luca Borradori, Masayuki Amagai, Takashi Hashimoto, Frédéric Caux, Branka Marinovic, Animesh A Sinha, Michael Hertl, Philippe Bernard, David Sirois, Giuseppe Cianchini, Janet A Fairley, Marcel F Jonkman, Amit G Pandya, David Rubenstein, Detlef Zillikens, Aimee S Payne, David Woodley, Giovanna Zambruno, Valeria Aoki, Carlo Pincelli, Luis Diaz, Russell P Hall, Michael Meurer, Jose M Mascaro Jr, Enno Schmidt, Hiroshi Shimizu, John Zone, Robert Swerlick, Daniel Mimouni, Donna Culton, Jasna Lipozencic, Benjamin Bince, Sergei A Grando, Jean-Claude Bystryn, Victoria P Werth
Abstract
Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies.
Conflict of interest statement
Conflicts of interest: None declared.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Figures
Source: PubMed